|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|||||||||||||
|
|
Research
Areas > Current Project >
Publications
Publications: 1. Khalid Abu Ajaj,
Ralph Graeser, Felix Kratz Breast Cancer Research and Treatment, 2011, submitted, Abstract 2. Khalid Abu Ajaj, Naser El-Abadla, Pia
Welker, Samar Azab, Reiner Zeisig, Iduna Fichtner, Felix Kratz European Journal of Cancer, 2011, in press. Abstract 3. Bakheet Elsadek, Chizuko Tsurumi, Khalid Abu Ajaj,
André Warnecke, Clemens Unger, Tahia Saleem, Felix Kratz Prostate
Cancer and Prostatic Diseases, 2011, 14 (1), 14–21. Abstract 4. Bakheet Elsadek, Ralph
Graeser, Norbert Esser, Cynthia Schäfer-Obodozie, Khalid Abu Ajaj,
Clemens Unger, André Warnecke, Tahia Saleem, Nagla
El-Melegy, Hafez Madkor, Felix Kratz European
Journal of Cancer, 2010, 46 (18), 3434–3444. Abstract 5. Khalid Abu Ajaj, Martin Biniossek, Felix Kratz Bioconjugate Chemistry, 2009, 20 (2), 390–396. Abstract 6. Khalid Abu Ajaj, Felix Kratz Bioorganic & Medicinal Chemistry Letters, 2009, 19 (3), 955–1000. Abstract 7. Khalid Abu Ajaj, Ralph Graeser, Iduna Fichtner, Felix Kratz Cancer Chemotherapy & Pharmacology, 2009, 64 (2),
413–418. Abstract Review: 1. Khalid Abu Ajaj, Felix Kratz book chapter ‘‘Clinical Experience with Drug-Polymer
Conjugates’’ in Drug Delivery in Oncology – From Basic
Research to Cancer Therapy Wiley-VCH, 2011, 839–884. Abstract, Flyer 2 Felix Kratz, Khalid Abu Ajaj, André Warnecke Expert Opinion on Investigational Drugs, 2007, 16 (7), 1037–1058. Abstract Poster: 1. Khalid Abu Ajaj, Ralph Graeser, Yeonyu Lee, Felix Kratz ‘‘Prodrug-mediated reversal of
multidrug resistance in breast cancer cells’’ AACR Annual Meeting 2012 Chicago, IL, USA, March 31–April 4, 2012, submitted 2. Teuta Opacak-Bernardi, Leslie
Robinson, Khalid Abu Ajaj, Felix Kratz,
Drazen Raucher ‘‘In vitro evaluation of a thermally
targeted conjugate of a highly potent doxorubicin derivative’’ AACR Annual Meeting 2011 Orlando, Florida, USA, April 2–6, 2011 3. Khalid Abu Ajaj, Naser-El-Abadla, Pia Welker, Iduna Fichtner, Felix Kratz ‘‘Biological evaluation of folate
prodrugs with a highly toxic derivative of doxorubicin’’ AACR Annual Meeting 2011 Orlando, Florida, USA, April 2–6, 2011 4. Khalid Abu
Ajaj, Cynthia Schaefer-Obodozie, Norbert Esser,
Felix Kratz ‘‘Development of macromolecular
prodrugs with proteasome inhibitors’’ 8th International Symposium on Polymer
Therapeutics: From Laboratory to Clinical
Practice 5. Bakheet Elsadek, Nagla El Melegy, Hafez Madkor,
Felix Kratz ‘‘Development of a novel
water-soluble prodrug of paclitaxel that is cleaved by prostate-specific antigen
(PSA): In vitro and in vivo evaluation’’ AACR Annual Meeting 2010 Washington DC, USA, April
17–21, 2010 6. Khalid Abu Ajaj,
‘‘Development of a dual-acting prodrug with doxorubicin and the
P-glycoprotein inhibitor ONT-093 for circumventing
multidrug resistance’’ AACR Annual Meeting 2009 Denver, Colorado, USA,
April 18–22, 2009 7. Khalid Abu Ajaj,
Felix Kratz
‘‘Development of prodrugs for combination chemotherapy’’ AACR Annual Meeting 2009 Denver, Colorado, USA,
April 18–22, 2009 8. Khalid Abu Ajaj,
"In vitro and in vivo study of an albumin-binding prodrug of
doxorubicin that is cleaved by cathepsin B" AACR Annual Meeting 2009 Denver, Colorado, USA,
April 18–22, 2009 9. Felix Kratz, Claudia Ryppa, Khalid Abu Ajaj
‘‘Development of ligand-based and dual acting prodrugs as the next
generation of albumin binding prodrugs’’ 7th International Symposium on Polymer Therapeutics:
From Laboratory to Clinical Practice 10. Khalid Abu Ajaj, Ralph Graeser, Christoph Schaechtele, Felix Kratz ‘‘Development of prodrugs for combination
chemotherapy’’ AACR Annual Meeting 2008 San Diego, CA, USA, April 12–16,
2008 11. Khalid Abu Ajaj, Felix Kratz ‘‘Development of new albumin-binding
dual acting prodrugs to overcome P-glycoprotein-mediated multidrug
resistance ’’ AACR Annual Meeting 2007 Los Angeles, CA, USA, April 14–18,
2007 |
|
||||||||||||||||
|
terms and conditions | ÇÊÝÇÞíÉ ÇÓÊÎÏÇã ÇáãæÞÚ | rechtlicher Hinweis |
|
AbuAjaj.com©
2001-2010 last change 24.11.2011 |